General MedicationsTRANSDERMALStandard
SECUADO
ASENAPINE
Standard Dose
7.6MG/24HR
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview SECUADO is listed in Drugs@FDA under application 212268 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient ASENAPINE Form and strength SYSTEM;TRANSDERMAL - 7.6MG/24HR Sponsor HISAMITSU Submission history Latest submission status date: 2025-01-22 00:00:00.
Structured Monograph
Clinical summary
Approval overview SECUADO is listed in Drugs@FDA under application 212268 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient ASENAPINE Form and strength SYSTEM;TRANSDERMAL - 7.6MG/24HR Sponsor HISAMITSU Submission history Latest submission status date: 2025-01-22 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.